Literature DB >> 21975934

c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M.

Charlene E Kan1, Rocky Cipriano, Mark W Jackson.   

Abstract

Cytokines play an important role in creating an inflammatory microenvironment, which is now considered a hallmark of cancer. Although tumor cells can exploit cytokine signaling to promote growth, invasion, and metastasis, the response of normal and premalignant epithelial cells to cytokines present in a developing tumor microenvironment remains unclear. Oncostatin M (OSM), an IL-6 family cytokine responsible for STAT3 activation, has been implicated in cancer development, progression, invasion, and metastasis. Paradoxically, OSM can also suppress the growth of normal cells and certain tumor-derived cell lines. Using isogenic human mammary epithelial cells (HMEC) at different stages of neoplastic transformation, we found that OSM signaling suppressed c-MYC expression and engaged a p16- and p53-independent growth arrest that required STAT3 activity. Inhibition of STAT3 activation by expressing a dominant-negative STAT3 protein or a STAT3-shRNA prevented the OSM-mediated arrest. In addition, expression of c-MYC from a constitutive promoter also abrogated the STAT3-mediated arrest, and strikingly, cooperated with OSM to promote anchorage-independent growth (AIG), a property associated with malignant transformation. Cooperative transformation by c-MYC and OSM required PI3K and AKT signaling, showing the importance of multiple signaling pathways downstream of the OSM receptor in defining the cellular response to cytokines. These findings identify c-MYC as an important molecular switch that alters the cellular response to OSM-mediated signaling from tumor suppressive to tumor promoting. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975934      PMCID: PMC4116142          DOI: 10.1158/0008-5472.CAN-10-3860

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Delineating oncogene/tumor suppressor interactions in human mammary epithelial cells.

Authors:  Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2011-08-15       Impact factor: 4.534

3.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

4.  TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells.

Authors:  Rocky Cipriano; Charlene E Kan; James Graham; David Danielpour; Martha Stampfer; Mark W Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

Review 5.  Of mice and Myc: c-Myc and mammary tumorigenesis.

Authors:  M Hunter Jamerson; Michael D Johnson; Robert B Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

6.  Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells.

Authors:  James C Garbe; Sanchita Bhattacharya; Batul Merchant; Ekaterina Bassett; Karen Swisshelm; Heidi S Feiler; Andrew J Wyrobek; Martha R Stampfer
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

7.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

Review 8.  Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis.

Authors:  Dae Joon Kim; Keith S Chan; Shigetoshi Sano; John Digiovanni
Journal:  Mol Carcinog       Date:  2007-08       Impact factor: 4.784

9.  Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation.

Authors:  A J Brenner; M R Stampfer; C M Aldaz
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

10.  Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.

Authors:  Todd M Savarese; Cara L Campbell; Catherine McQuain; Kathryn Mitchell; Rachel Guardiani; Peter J Quesenberry; Beth E Nelson
Journal:  Cytokine       Date:  2002-03-21       Impact factor: 3.861

View more
  16 in total

1.  Oncostatin M activation of Stat3:Smad3 complexes drives senescence.

Authors:  Alyssa A La Belle; William P Schiemann
Journal:  Cell Cycle       Date:  2017-01-27       Impact factor: 4.534

2.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

3.  Effect of human papillomavirus 16 oncoproteins on oncostatin M upregulation in oral squamous cell carcinoma.

Authors:  Jureeporn Chuerduangphui; Chamsai Pientong; Ponlatham Chaiyarit; Natcha Patarapadungkit; Apinya Chotiyano; Bunkerd Kongyingyoes; Supannee Promthet; Piyawut Swangphon; Weerayut Wongjampa; Tipaya Ekalaksananan
Journal:  Med Oncol       Date:  2016-06-27       Impact factor: 3.064

4.  Aberrant Induction of a Mesenchymal/Stem Cell Program Engages Senescence in Normal Mammary Epithelial Cells.

Authors:  Benjamin L Bryson; Ilaria Tamagno; Sarah E Taylor; Neetha Parameswaran; Noah M Chernosky; Nikhila Balasubramaniam; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2020-12-22       Impact factor: 5.852

5.  Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.

Authors:  Jacob M Smigiel; Neetha Parameswaran; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2017-01-04       Impact factor: 6.333

Review 6.  The enigmatic cytokine oncostatin m and roles in disease.

Authors:  Carl D Richards
Journal:  ISRN Inflamm       Date:  2013-12-08

7.  HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.

Authors:  Damian J Junk; Benjamin L Bryson; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2014-03-26       Impact factor: 6.639

Review 8.  STAT3 and epithelial-mesenchymal transitions in carcinomas.

Authors:  Michael K Wendt; Nikolas Balanis; Cathleen R Carlin; William P Schiemann
Journal:  JAKSTAT       Date:  2014-04-29

9.  Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues.

Authors:  Daniel A Smith; Atsushi Kiba; Yang Zong; Owen N Witte
Journal:  Mol Cancer Res       Date:  2013-07-18       Impact factor: 5.852

10.  STAT3 in Cancer-Friend or Foe?

Authors:  Hai-Feng Zhang; Raymond Lai
Journal:  Cancers (Basel)       Date:  2014-07-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.